Climb Bio, Inc. 8K

Climb Bio reported Q2 2026 financial results, detailed clinical and corporate pipeline milestones for budoprutug and CLYM116, closed a $110 million private placement, and appointed Breanna O’Reilly, Ph.D. to its Board, extending its cash runway into the second half of 2028.

On August 6, 2026, Climb Bio, Inc. reported its second quarter 2026 financial results and provided business updates, highlighting ongoing clinical progress for its lead programs budoprutug and CLYM116, including upcoming data readouts and trial initiations across IgA nephropathy, primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, alongside disclosure of an April 29, 2026 private placement financing that raised approximately $110 million and extended the company’s cash runway into the second half of 2028, and the June 2026 appointment of Breanna O’Reilly, Ph.D. of RA Capital Management to its Board of Directors.

Filing Facts

CIK

1768446

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-336762

Alert Tier

6